Lantheus HoldingsLNTH +0.19%82 Altman Z2-Score is 5.06 as of Jul. 02, 2026, which is 169% above its 10-year median of 1.88. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.85 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 996 Drug Manufacturers companies, Lantheus Holdings ranks better than 62.55% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Lantheus Holdings has a Altman Z2-Score of 5.06, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Lantheus Holdings's Altman Z2-Score or its related term are showing as below:
LNTH'
s Altman Z2-Score Range Over the Past 10 Years
Min: -1.54 Med: 1.88 Max: 7.18
Current: 5.06
During the past 13 years, Lantheus Holdings's highest Altman Z2-Score was 7.18. The lowest was -1.54. And the median was 1.88.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Lantheus Holdings Altman Z2-Score Related Terms
Lantheus Holdings Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs LQDA, HIMS, AMRX: Altman Z2-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Lantheus Holdings's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.2596
+
3.26
*
0.34
+
6.72
*
0.1677
+
1.05
*
1.0688
=
5.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Lantheus Holdings (LNTH) has a Altman Z2-Score of 5.06 as of Jul. 02, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Lantheus Holdings and its competitors. This is 169% above median its historical median of 1.88. According to the industry distribution chart, Lantheus Holdings ranks #373 out of 996 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is Lantheus Holdings' Altman Z2-Score too high?
Lantheus Holdings' current Altman Z2-Score of 5.06 is 169% above median its 10-year median of 1.88. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Lantheus Holdings' value of 5.06 is 30.9% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #373 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Altman Z2-Score compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #373 out of 996 companies for Altman Z2-Score. This puts Lantheus Holdings in the upper half of its industry. The industry median Altman Z2-Score is 3.87. Lantheus Holdings' value of 5.06 is 30.9% above this benchmark. While the company's 10-year median is 1.88 vs. the industry median of 3.87, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Altman Z2-Score of 5.06 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Altman Z2-Score is 5.06, which is 169% above median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $109.14 — trading 20.1% above its estimated fair value. The current Altman Z2-Score is 5.06, which is 169% above median its 10-year median of 1.88 and 30.9% above the Drug Manufacturers industry median of 3.87. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Altman Z2-Score is 5.06 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $109.14 is trading 20.1% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Altman Z2-Score: 5.06 (169% above median its 10-year median of 1.88)
GF Value™: $90.85 vs. price of $109.14 (20.1% above fair value)
Industry Position: 30.9% above the Drug Manufacturers median (#373 of 996)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
